MTOR and leukemia: The activation of the mTOR pathway was confirmed in Kmt2d‐deficient leukemia cells, as shown by Western blots with antiphosphorylated ribosomal protein S6, a substrate of direct mTORC1 target S6K1 (Figure 4B).